4184-73-0Relevant articles and documents
Semicarbazides as gel forming agents for common solvents and liquid crystals
Deindoerfer, Pia,Geiger, Thomas,Schollmeyer, Dieter,Ye, Jian Hui,Zentel, Rudolf
, p. 351 - 358 (2007/10/03)
This paper describes the synthesis of 14 new gelling agents with semicarbazide groups as H-bonding motifs and alkyl- and/or azobenzene side groups. They gel solvents like decaline, 1,2-dichlorobenzene and toluene and liquid crystalline mixtures. X-Ray structure analysis shows that the semicarbazides are connected by H-bonds, each molecule to four neighbours. As a result a ribbon is formed with a core of H-bonded semicarbazide groups and alkyl chains sticking to the side. IR measurements show an unchanged H-bonding motif in large crystals and in the gel fibres, even in LC-mixture. During heating the gel melts (rheology), while the H-bonding motif of the crystal disappears (IR and DSC measurements). First experiments show that these gel-forming agents can be used to gel LC-phases and to stabilise the director pattern present during gel formation. The Royal Society of Chemistry 2006.
Piperidine-containing histamine H3 receptor antagonists of the carbamate series: The alkyl derivatives
Lazewska,Kiec-Kononowicz,Elz,Pertz,Stark,Schunack
, p. 403 - 410 (2007/10/03)
A series of N-alkyl urethanes, potential histamine H3 receptor antagonists, was prepared. Carbamate derivatives were synthesized from appropriate isocyanates and N-piperidinoalkan-1-ols. The novel compounds were evaluated for histamine H3 receptor activity in vitro on the guinea pig ileum. Some selected compounds were tested in vivo after p.o. application to mice and in vitro for selectivity towards other histamine receptors (H 1, H2) in functional assays in the guinea pig. The most potent H3 receptor antagonist in vitro was compound 14 (pA 2 = 7.2). Compound 14 was equipotent at M3 receptors and lacked H3 receptor activity in vivo. Predictions of octanol-water partition coefficient (Pallas) and metabolic fate (MetabolExpert, METEOR) were used to explore potential reasons for this absence of in vivo activity.
Compounds having reversible inhibiting activity of carnitine palmitoyl-transferase
-
, (2008/06/13)
Compounds of formula (I) wherein the groups are as defined in the description are disclosed. The compounds of formula (I) are endowed with reversible inhibiting activity of carnitine palmitoyl-transferase and are useful in the preparation of medicaments useful in the pathologies related to a hyperactivity of carnitine palmitoyl-transferase, such as hyperglycemia, diabetes and pathologies related thereto, heart failure, ischemia.